N/A N=57 Assessing Gestational Age in First Trimester Pregnancies Using Ultrasound
Pregnancy Early
Primary: Can Both Transabdominal Ultrasounds See a Gestational Sac and Yolk Sac or Embryo? — 51 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=12 Study to Evaluate the Safety, Local and Systemic Tolerability, and Pharmacokinetics of Multiple-Dose Topical Administration of PF-07038124 in Japanese Healthy Participants
Healthy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 0; 0; 1; 0 Participants
Phase 3 N=62 RESCUE and REVERSE Long-term Follow-up
Leber Hereditary Optic Neuropathy
Primary: Ocular Adverse Events (AEs) — 5; 1 eyes
Phase 2 N=78 Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis
HIV Coinfection · Aids/Hiv Problem · Tuberculosis, Pulmonary
Primary: Sputum Culture — 15; 20; 14 Participants
N/A N=666 Mental Health Among Patients, Providers, and Staff During the COVID-19 Era
Covid19 · Mental Health
Primary: Loneliness as Measured by the National Institutes of Health (NIH) Toolbox Social Relationship Scale for Loneliness — 64.4; 64.4; 62.6; 62.5 T-score — p=0.31
Phase 1 N=66 A Study of Two Formulations of LY3074828 in Healthy Participants
Healthy
Primary: Pharmacokinetics: Maximum Concentration (Cmax) of LY3074828 by Device — 22.2; 18.7 micrograms per milliliter (μg/mL)
N/A N=28 REACH VET Implementation Program Evaluation
Suicide
Primary: Coordinator Assigned Post-Implementation — 97.6 percentage — p=.302
Phase 1 N=54 A Study of Two Different Formulations of LY3074828 in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Dose-normalized Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (DN-AUC[0-tlast]) of LY3074828…
Phase 2 N=269 A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Chronic Kidney Diseases · Pruritus
Primary: Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score During Week 12 — -3.99; -3.84; -4.42; -3.32 score on…
Phase 3 N=332 Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Strongyloides Stercoralis Infection
Primary: Cure Rate Against Strongyloides Stercoralis — 94.8; 99.4 percentage of participants
Phase 1 N=6 Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy
Japanese Patients With ALS
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone — 2300 ng·h/mL
Phase 3 N=26 Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo. — 0; -0.66 % HbA1c
Phase 2 N=102 Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
Acute ST Segment Elevation Myocardial Infarction
Primary: High-sensitive С-reactive Protein (hsCRP) Area Under Curve (AUC) From Baseline Until Day 14 (Multiple Imputation Procedure) — 106.84; 107.65; 184.30 mg*day/L
Phase 1 N=9 Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis
Japanese Patients With ALS
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone — 1719 ng·h/mL
N/A N=154 RoBotic TCD Ultrasound BubbLe Study Compared to Transthoracic Echocardiography for Detection of Right to Left Shunt
Embolic Stroke of Undetermined Source · Transient Ischemic Attack · Right-To-Left Atrial Shunt
Primary: Percent Detection of Right to Left Shunt (RLS)/Patent Foramen Ovale (PFO) Using Robotic Assisted TCD (Study Device) — 74; 47; 24; 97 Participants — p=<0.001